98%
921
2 minutes
20
Background: The introduction of multi-agent chemotherapy and radiation therapy has facilitated potential resection with curative intent in selected locally advanced pancreatic cancer (LAPC) patients with excellent outcomes. Nevertheless, there remains a remarkable lack of consensus on the management of LAPC. We sought to describe the outcomes of patients with LAPC and objectively define the multidisciplinary selection process for operative exploration based on anatomical factors.
Methods: Consecutive patients with LAPC were evaluated for pancreatic surgery in the multidisciplinary clinic of a high-volume institution, between 2013 and 2018. Prospective stratification (LAPC-1, LAPC-2, and LAPC-3), based on the involvement of regional anatomical structures, was performed at the time of presentation prior to the initiation of treatment. Resection rates and patient outcomes were evaluated and correlated with the initial anatomic stratification system.
Results: Overall, 415 patients with LAPC were included in the study, of whom 84 (20%) were successfully resected, with a median overall survival of 35.3 months. The likelihood of operative exploration was associated with the pretreatment anatomic LAPC score, with a resection rate of 49% in patients classified as LAPC-1, 32% in LAPC-2, and 11% in LAPC-3 (p < 0.001). Resected patients with improvement of the LAPC score at the time of exploration had significantly longer median overall survival compared with those with no change or progression of LAPC score (60.7 vs. 29.8 months, p = 0.006).
Conclusions: Selected patients with LAPC can undergo curative-intent surgery with excellent outcomes. The proposed Johns Hopkins anatomic LAPC score provides an objective system to anticipate the probability of eventual surgical resection after induction therapy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688211 | PMC |
http://dx.doi.org/10.1245/s10434-021-10663-1 | DOI Listing |
World J Urol
August 2025
Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Objective: To evaluate the oncological outcomes and continence recovery of neoadjuvant hormonal therapy (NHT) before robot-assisted laparoscopic radical prostatectomy (RARP) with neurovascular bundle (NVB) preservation in patients with locally advanced prostate cancer (LAPC).
Methods: Of the 576 patients with LAPC who underwent RARP during January 2016-March 2024, those who received NHT before RARP with NVB preservation (NVB-RARP) were propensity score (PS)-matched with those undergoing RARP without NVB preservation (NNVB-RARP) based on preoperative and histological characteristics. Clinical and biochemical recurrence results were evaluated post-surgically, and postoperative continence was analyzed in the two groups using Kaplan-Meier curves.
Clin Transl Gastroenterol
August 2025
Beaujon Hospital, Endoscopy Unit, 92100 Clichy, France.
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with poor prognosis and limited treatment options. Electroporation-based therapies, such as electrochemotherapy (ECT) and irreversible electroporation (IRE) could be promising alternatives. ECT combines reversible electroporation with chemotherapy, enhancing intracellular drug uptake, while IRE leads to non-thermal tumor ablation.
View Article and Find Full Text PDFJ Gastrointest Cancer
August 2025
AIG Hospitals, Hyderabad, India.
Background: Pancreatic cancer is among the most lethal malignancies, with limited real-world data comparing frontline chemotherapy regimens across disease stages. FOLFIRINOX and gemcitabine plus nab-paclitaxel (G + P) are standard treatments with differing toxicity profiles and outcomes. This study evaluated the comparative efficacy and safety of these regimens in metastatic, locally advanced (LAPC), and borderline resectable pancreatic cancer (BRPC).
View Article and Find Full Text PDFCancers (Basel)
August 2025
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Background: Radiation dose escalation for locally advanced pancreatic cancer (LAPC) using stereotactic magnetic resonance (MR)-guided online adaptive radiation therapy (SMART) or computed tomography (CT)-guided moderately hypofractionated ablative radiation therapy (HART) can achieve favorable outcomes although have not previously been compared.
Methods: We performed a multi-center retrospective analysis of SMART (50 Gy/5 fractions) vs. HART (75 Gy/25 fractions or 67.
Cancers (Basel)
July 2025
Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Rikshospitalet, 0372 Oslo, Norway.
: Treatment of borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancer involves neoadjuvant chemotherapy followed by complex surgery, posing significant risks of toxicity, complications, and changes in quality of life (QoL). This study aims to investigate the impact of neoadjuvant chemotherapy followed by resection on overall survival (OS) and QoL. : Consecutive patients with BRPC and LAPC included in a population-based study (NORPACT-2) from January 2018 to December 2020 were reviewed.
View Article and Find Full Text PDF